Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tharimmune Inc THAR

Healthcare Biotechnology
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active... see more

Recent & Breaking News (NDAQ:THAR)

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

GlobeNewswire July 6, 2023

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

GlobeNewswire May 15, 2023

Hillstream BioPharma Announces Closing of Public Offering of Common Stock

GlobeNewswire May 2, 2023

Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences

GlobeNewswire May 2, 2023

Hillstream BioPharma Announces Pricing of Public Offering

GlobeNewswire April 27, 2023

Hillstream BioPharma Announces Proposed Public Offering

GlobeNewswire April 27, 2023

Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism

GlobeNewswire April 13, 2023

Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow

Accesswire April 12, 2023

Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data

GlobeNewswire April 10, 2023

Hillstream BioPharma to Participate in Two Major Industry Conferences in April 2023

GlobeNewswire March 28, 2023

Hillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023

GlobeNewswire February 28, 2023

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

GlobeNewswire February 15, 2023

Hillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ET

GlobeNewswire February 13, 2023

Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer

GlobeNewswire February 13, 2023

In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer

GlobeNewswire February 10, 2023

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias

GlobeNewswire February 8, 2023

Hillstream BioPharma to Host Virtual R&D Day to Showcase its Emerging Immuno-oncology Pipeline Targeting Drug-Resistant Cancers

GlobeNewswire February 6, 2023

Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers

GlobeNewswire January 31, 2023

Hillstream BioPharma to Present at the Virtual Sidoti Micro-Cap Conference on January 18-19, 2023

GlobeNewswire January 17, 2023

Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies(TM) (HSB-1940) against PD-1, by combining Quatramers(TM) with OmniAb's Picobodies(TM), via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets

GlobeNewswire December 1, 2022